Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

14.07 -7.89 (-35.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,871,899
Open 16.98
Bid (Size) 14.00 (16)
Ask (Size) 14.04 (5)
Prev. Close 21.97
Today's Range 12.81 - 19.18
52wk Range 16.88 - 150.48
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit

Performance

YTD
-88.7%
-88.7%
1 Month
-34.7%
-34.7%
3 Month
-73.8%
-73.8%
6 Month
-88.0%
-88.0%
1 Year
-90.4%
-90.4%

More News

Read More
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Top stock movements in today's session.
Via Chartmill
Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier
Via Stocktwits
Stocks Slip As Netflix Fails To Impress, Bitcoin Eyes Negative Week: What's Moving Markets Friday?
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market
Via Stocktwits
Topics Death
Friday's session: top gainers and losers
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
Sarepta's Setback Deepens With Another Gene Therapy Fatality
Via Benzinga
Gapping stocks in Friday's session
Via Chartmill
Sarepta Therapeutics Crashes 26% After A Third Gene Therapy Patient Dies
Via Investor's Business Daily
Topics Death Stocks
Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Get insights into the top gainers and losers of Friday's pre-market session.
Via Chartmill
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Via Benzinga
Topics Death
Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Via Benzinga
AAR, Lucid Group, Monarch Casino & Resort And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Assessing Sarepta Therapeutics: Insights From 35 Financial Analysts
Via Benzinga
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 14.07
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 07/18/25 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.31B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.